Search Bar & Filters
Found 10 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effect of a triple therapy inhaler containing budesonide, glycopyrronium, and formoterol fumarate BGF MDI 32014.49.6 g compared to a dual therapy inhaler with glycopyrronium and formoterol fumarate GFF MDI 14.49.6 g on heart and lung outcomes in adults with chronic obstructive pulmonary disease COPD who have increased cardiopulmonary risk. This is a Phase III randomized, double-blind, parallel group, multi-center study designed to assess these treatments over an extended period. Participants will be randomly assigned to receive either the triple therapy BGF MDI or the dual therapy GFF MDI, each administered twice daily. The study aims to track the time to first severe cardiac or COPD event over up to three years. Both treatments involve pressurized inhalation suspensions delivered by metered-dose inhalers, and the study includes ongoing monitoring for up to three years during which various cardiopulmonary events and exacerbations will be recorded. During the study, participants will attend visits where their inhaler technique, lung function, blood markers such as eosinophil counts, and COPD assessment test scores will be evaluated. Researchers will measure outcomes including time to severe COPD exacerbations, cardiac events, cardiopulmonary death, and hospitalizations related to heart issues. Safety and efficacy will be closely monitored throughout the study duration, which may last up to three years, with regular follow-up assessments conducted in person or virtually as needed.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of tacabrutideg compared with pirtobrutinib in adults with relapsed or refractory chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL who have previously been treated with a covalent Bruton tyrosine kinase inhibitor cBTKi. This phase 3, open-label, randomized study focuses on patients whose disease has relapsed or not responded after at least one line of therapy including a cBTKi. Participants will be randomly assigned to receive either tacabrutideg or pirtobrutinib, both given orally. The study compares the two drugs in parallel groups to assess their safety and efficacy over the course of treatment. During the study, participants will be closely monitored for disease progression, survival, response rates, duration of response, time to next treatment, adverse events, and quality of life using standardized questionnaires. These assessments will be conducted for up to approximately 3 years to evaluate the long-term outcomes and safety profiles of the treatments.
Actively Recruiting
Researchers are evaluating the efficacy and safety of a combination budesonide and albuterol metered dose inhaler BDA MDI compared with an albuterol sulfate AS metered dose inhaler in symptomatic Chinese adults with asthma. This randomized, double-blind, Phase III study aims to reduce the risk of severe asthma exacerbations in participants who have had asthma diagnosed for at least 12 months and currently use maintenance therapies. The study involves about 1000 eligible participants randomly assigned to receive either BDA MDI 160180 mcg delivered as two actuations of 8090 mcg or AS MDI 180 mcg delivered as two actuations of 90 mcg. Both treatments are used as needed for asthma symptoms or before exercise. The trial includes a screening period lasting 14 to 28 days, followed by a treatment period of at least 24 weeks and up to 52 weeks, and concludes with a safety follow-up about two weeks after the last treatment visit. Participants will be assessed through various visits during the study, including evaluations of lung function, asthma control questionnaires ACQ-5 and ACQ-7, and monitoring of severe asthma exacerbations. The primary outcome is the time to the first severe asthma exacerbation over the treatment period. Secondary outcomes include the rate of exacerbations, steroid exposure, and patient-reported measures of asthma control and quality of life. Safety and adherence are closely monitored throughout the study duration.
Actively Recruiting
Researchers are conducting a large observational study called the China HeadAche Disorders Registry CHAIRS to better understand primary headaches and medication-overuse headaches MOH in patients aged 12 years and older. The study aims to collect detailed information including biomarkers, brain imaging, cognitive and genetic data, as well as social, demographic, medical, and treatment-related data. Long-term follow-up is planned to observe outcomes related to headache disorders over many years. Participants include those with various types of primary headaches such as migraine, tension-type headache, new daily persistent headache, and MOH. The study includes behavioral follow-up visits at multiple time points monthly for the first 18 months, then at 24 months, and annually thereafter. Some participants are observed during routine clinical use of treatments like Yangxue Qingnao Granules, Erenumab, and Eptinezumab, with treatment decisions made by their physicians and outcomes tracked over 12 weeks or longer. Throughout the study, participants undergo periodic assessments including MRI scans, cognitive tests like the Montreal Cognitive Assessment MoCA and Mini-Mental State Exam MMSE, and questionnaires evaluating headache impact, anxiety, depression, quality of life, sleep quality, and fatigue. Data on headache frequency, severity, medication use, and biological samples are collected. Follow-up can extend up to 10 years, allowing researchers to monitor long-term changes and outcomes related to headache disorders and treatments.
Actively Recruiting
This trial studies patients with HER2-positive advanced breast cancer who have unresectable, locally advanced, or metastatic invasive breast cancer. Researchers are comparing two drug treatments, TQB2102 injection and trastuzumab emtansine injection, to evaluate their effects on progression-free survival. This is a randomized, open-label, phase III clinical trial designed to assess the efficacy and safety of these treatments in this patient population. Participants are randomly assigned to receive either TQB2102 or trastuzumab emtansine by intravenous infusion. TQB2102 is given at a dose of 6 mgkg every 3 weeks, while trastuzumab emtansine is given at 3.6 mgkg every 3 weeks. Each infusion cycle lasts 3 weeks, and treatment continues according to the protocol. The trial includes multiple centers and uses positive drug control design. During the study, participants will be monitored for progression-free survival assessed by an Independent Review Committee over 30 months. Additional evaluations include overall survival, duration and rate of response, clinical benefit rate, and safety assessments of adverse events. Antibody levels and immune responses will be measured at various cycles. Follow-up for survival outcomes may continue up to 5 years. Participants will have regular visits for assessments, safety monitoring, and laboratory tests throughout the trial duration.
Actively Recruiting
Hepatocellular carcinoma HCC is a common and serious liver cancer in China with a high death rate. Early recurrence of the cancer is closely linked to how aggressive the tumor is. Microvascular invasion MVI, which means cancer cells are found in small blood vessel branches near the tumor, is an important sign of aggressive disease and is linked to early return of cancer after surgery. Currently, MVI can only be definitively diagnosed after surgery, and there are no reliable methods to predict it before surgery. This research aims to create and test an advanced computer-aided diagnosis CAD system using artificial intelligence and detailed CT images taken before surgery to predict MVI in patients with HCC. The CAD system combines multiple types of imaging features including deep learning-extracted patterns, specific tumor characteristics like shape and texture, and expert-defined factors such as tumor edge clarity and blood vessel relationships. It uses a hybrid model combining convolutional neural networks, Transformer modules, and graph neural networks to analyze tumor details and surrounding areas. The system also provides confidence levels and visual outputs to help doctors understand and trust the predictions. This study will observe its performance across multiple hospitals by comparing the systems predictions with actual pathology results after surgery. Participants are adults aged 18 and older who are scheduled for surgical removal of HCC and have preoperative multiphase CT scans and pathological evaluation data available. Researchers will collect imaging, clinical, and pathology data to evaluate how accurately the CAD system predicts MVI compared to standard pathology. The main measures include the systems accuracy and the area under the receiver operating characteristic curve AUC within one month after surgery. Additional measures include sensitivity, specificity, and calibration. The study will also examine how the systems predictions might influence surgical decision-making and risk assessment in real-world practice.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of neuroendoscopic surgery compared to traditional craniotomy for treating large intracerebral hemorrhage. This trial addresses the lack of prospective randomized studies on surgical methods for this condition, aiming to provide clearer guidance for treatment decisions. Previous studies suggest neuroendoscopic surgery may reduce surgery time and blood loss while improving recovery and quality of life. Participants will be randomly assigned to one of two groups one receiving neuroendoscopic surgery to remove the brain hematoma, and the other undergoing craniotomy for the same purpose. Both groups will receive standard medical care after surgery. The trial is conducted across multiple centers and includes a single-blinded design. During the study, participants will be monitored for several outcomes, including neurological recovery using the Modified Rankin Scale at 180 days, mortality rates at 30, 90, and 180 days, cognitive function with the Mini-Mental State Examination, and quality of life assessments. Researchers will also track hospital and ICU stay lengths, operation duration, and bleeding during surgery. Follow-up assessments will occur up to 180 days after treatment to evaluate safety and effectiveness.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the use of chest X-ray CXR in a large-scale study to screen for thoracic diseases in adults. This observational study involves participants who come for routine health exams and aims to confirm suspected abnormalities with more precise methods like chest CT scans or clinical follow-up. The goal is to determine how well CXR works in detecting early lung, pleural, and heart problems and to provide evidence for its cost-effectiveness and feasibility in public health screening. Participants will undergo digital chest X-rays during their health examinations. When abnormalities are suspected, these findings will be verified using a gold standard reference such as a chest CT scan or through clinical follow-up procedures. The study gathers data across multiple centers to assess detection rates, diagnostic accuracy, false positives, and reading consistency among centers over an average period of one year. During the study, participants will have their chest X-rays analyzed and may be asked to undergo further scans or follow-ups if needed. Researchers will measure the overall detection rate of thoracic diseases, diagnostic performance metrics, and consistency across different centers. The study tracks participants for about one year to monitor these outcomes and better understand the benefits and limitations of using chest X-rays for disease screening.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of atorvastatin in adults aged 18 to 80 years who have experienced spontaneous intracerebral hemorrhage ICH within 3 to 24 hours of symptom onset. This multicenter, prospective, randomized, open-label, blinded end-point PROBE study aims to determine if atorvastatin improves clinical outcomes compared to best medical treatment alone. The study focuses on patients with hematomas located in the supratentorial region and uses the modified Rankin Scale mRS to measure functional outcomes at 90 days. Participants will be randomly assigned to one of two groups one group will receive atorvastatin 20 mg once daily for 21 days along with best medical treatment BMT following current guidelines for ICH, while the other group will receive only BMT. The treatment period lasts for 21 days starting within 48 hours of symptom onset or last known well time. The study will monitor changes in hematoma and perihematomal edema volumes at specific time points during the first week after hemorrhage. During the trial, participants will undergo assessments including computed tomography CT scans to confirm ICH diagnosis and measure hematoma size, as well as evaluations using the Glasgow Coma Scale and mRS. Researchers will track functional independence and neurological outcomes at 90 7 days. Safety and adverse events will be monitored throughout the study. The total follow-up includes primary and secondary outcome measurements up to three months after treatment to evaluate the impact of atorvastatin on recovery.
Actively Recruiting
Researchers are evaluating the safety, tolerability, and effectiveness of STSA-1002 injection in adults with acute respiratory distress syndrome ARDS. This Phase 3 randomized, double-blind, placebo-controlled trial aims to assess whether STSA-1002 can improve outcomes in patients suffering from this serious lung condition caused by respiratory viral infection. Participants must meet specific diagnostic criteria for ARDS and be within certain timeframes from symptom onset or worsening. The study compares two groups one receiving basal treatment plus STSA-1002 intravenous infusion and the other receiving basal treatment plus a placebo injection. Both treatment groups receive standard care alongside the investigational drug or placebo. The trial includes a 28-day period after the first dose, during which primary and secondary outcomes are measured, including mortality rates, respiratory support needs, and length of hospital stay. Participants will be closely monitored with evaluations including respiratory support assessments, organ function scores, and length of ICU and hospital stays. Researchers will track 28-day and 60-day mortality rates, changes in respiratory function, and ventilator-free days. The study involves baseline and follow-up tests and observations over the course of the treatment period to gather comprehensive safety and effectiveness data.